


# **The Regulator of Gastrointestinal Motility**

For the functional disorders of Gastrointestinal tract



**DEBRIDAT** 100mg Tablet  
**TRIMEBUTINE MALEATE** 200mg Tablet  
 Suspension 120ml



## Gastro-Intestinal Motility Regulator

**DEBRIDAT HAS ALREADY BEEN PRESCRIBED TO THOUSANDS OF PATIENTS IN MORE THAN 30 COUNTRIES**

- DEBRIDAT** improves gastrointestinal disturbance
- DEBRIDAT** improves 77% to 94% of the patients suffering from dyspepsia
- DEBRIDAT** decreases duodenal gastric reflux by decreasing or even eliminating the lack of duodenal-pyloric co-ordination and duodenal hypertonicity
- DEBRIDAT** proved its therapeutical efficacy in 67% to 90% of patients with irritable bowel syndrome
- DEBRIDAT** showed a distinctive lack of side effects as reported in worldwide studies
- DEBRIDAT** ensures efficacy with economy

### Usage of DEBRIDAT in following indications:

- Diarrhea
- Constipation
- Gastrointestinal motility
- Abdominal pain
- Abdominal distention
- Dyspepsia
- Irritable bowel syndrome
- Peptic ulcer
- Gastrointestinal tract disorders in pediatric patients

### DOSAGE:

1 or 2 tablets 3 times a day if pain accompanying peptic ulcer, IBS, Spastic colon, Nausea & Vomiting, Dyspepsia, Diarrhea, Constipation 3 to 6 tablets a day in divided dosage.

**IRRITABLE BOWEL SYNDROME (IBS)** Irritable bowel syndrome is certainly not unimportant in gastro-intestinal medicine. Spastic or irritable colon is one of the most common diagnoses made by gastroenterologists (19). The major complaints of patients suffering from the "functional disorder" are pain, flatulence and alternating constipation and diarrhoea. In order to evaluate the regulating activity of trimebutine, the postprandial Motor Index (MI) of IBS patients was investigated before and after treatment with trimebutine (20). In this experiment, trimebutine has been shown to significantly decrease the hypermotility of the colon to normal values (21). In opposite to other antispasmodics, Trimebutine proved to respect the physiological motility of normal subjects, the regularization of the motility is realised through a normalization of the frequency of colonic contractions. No change in amplitude was noticed. **POSTOPERATIVE PARALYTIC ILEUS** Whatever the quality, duration and type of digestive operation, postoperative periods are usually marked by nausea, abdominal pain and distention due to a reflex paralytic ileus. During this period, delayed expelling of gas and faeces is the surgeon's main concern (30). When treated with trimebutine the benefit in time required for intestinal transit restoration adds upto 20%. This recuperation period is also improved qualitatively (less pain and nausea) with trimebutine. (31, 32, 33, 34). **GASTROINTESTINAL DISORDERS IN PEDIATRICS** Trimebutine has been administered to children with gastrointestinal transit disorders or spastic colon without infectious or surgical origin. A remarkable efficacy has been revealed in children treated with trimebutine either in decreasing abdominal pain or in restoring the intestinal transit after episodes of diarrhoea or constipation (36, 37). **TERATOLOGY** Debridat has been widely prescribed for vomiting in pregnant women for many years. There has been no clinical or laboratory evidence of any untoward effect on the babies resulting from these pregnancies. **DISTRIBUTION** The tissue distribution studies demonstrated that concentrations found in the stomach and the intestinal walls were higher than those found in most other tissues. About 50% of the product was localized in the gastrointestinal tract at each studied time. Elimination of Trimebutine and its metabolites is essentially urinary (95%) and fecal elimination is about 5%. **TOXICOLOGY** For a man weighing 60 kg, the LD 50 would correspond to the oral administration of at least 3000 tablets. **SIDE EFFECTS** An additional benefit of the treatment with trimebutine which has been reported by many authors is distinctive lack of side effects. Pooled data from clinical studies involving 20,000 patients show a very low incidence of side effects (0.5%). These data enable us to state that trimebutine can be fully safely administered to adults or children of any age. **PRESENTATION:** Debridat 100mg available in 20 tablet in each pack, Debridat 200mg available in 20 tablet in each pack and Debridat 120ml suspension available.

Rs. 65.00 per bottle

Rs. 3.45 per tablet



Rs. 6.20 per tablet

### "Medicines For All"



**ZAFA Pharmaceutical Laboratories (Private) Limited.**  
 L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN)  
 Email: zafaph@cyber.net.pk, Website: www.zafa.com.pk

